1476-5381/asset/cover.gif?v=1&s=f56f5a76559ff1cebf2b6e329fe028f1e9e0f463 "British Journal of Pharmacology")
Current address: Human Physiology Section, Department of Experimental Medicine, University of Palermo, corso Tukory 129, 90134 Palermo, Italy.
1476-5381/asset/olbannerleft.gif?v=1&s=198ba9e64c782a75183a18cb494f9d10ecc901ea)
1476-5381/asset/olbannerright.gif?v=1&s=0b2124237bd4227e7991f1ea05cd4bed2496a9ae)
You have full text access to this OnlineOpen article
Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice
Article first published online: 29 JAN 2009
DOI: 10.1038/bjp.2008.177
2008 British Pharmacological Society
Additional Information
How to Cite
Capasso, R., Borrelli, F., Aviello, G., Romano, B., Scalisi, C., Capasso, F. and Izzo, A. A. (2008), Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. British Journal of Pharmacology, 154: 1001–1008. doi: 10.1038/bjp.2008.177
Publication History
- Issue published online: 29 JAN 2009
- Article first published online: 29 JAN 2009
- (Received March 10, 2008, Accepted March 28, 2008)
- Abstract
- Article
- References
- Cited By
Keywords:
- cannabidiol;
- cannabinoid receptors;
- fatty acid amide hydrolase;
- inflammatory bowel disease;
- intestinal transit;
- intestinal motility;
- intestine;
- phytocannabinoids
Background and purpose:
Cannabidiol is a Cannabis-derived non-psychotropic compound that exerts a plethora of pharmacological actions, including anti-inflammatory, neuroprotective and antitumour effects, with potential therapeutic interest. However, the actions of cannabidiol in the digestive tract are largely unexplored. In the present study, we investigated the effect of cannabidiol on intestinal motility in normal (control) mice and in mice with intestinal inflammation.
Experimental approach:
Motility in vivo was measured by evaluating the distribution of an orally administered fluorescent marker along the small intestine; intestinal inflammation was induced by the irritant croton oil; contractility in vitro was evaluated by stimulating the isolated ileum, in an organ bath, with ACh.
Key results:
In vivo, cannabidiol did not affect motility in control mice, but normalized croton oil-induced hypermotility. The inhibitory effect of cannabidiol was counteracted by the cannabinoid CB1 receptor antagonist rimonabant, but not by the cannabinoid CB2 receptor antagonist SR144528 (N-[-1S-endo-1,3,3-trimethyl bicyclo [2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide), by the opioid receptor antagonist naloxone or by the α2-adrenergic antagonist yohimbine. Cannabidiol did not reduce motility in animals treated with the fatty acid amide hydrolase (FAAH) inhibitor N-arachidonoyl-5-hydroxytryptamine, whereas loperamide was still effective. In vitro, cannabidiol inhibited ACh-induced contractions in the isolated ileum from both control and croton oil-treated mice.
Conclusions and implications:
Cannabidiol selectively reduces croton oil-induced hypermotility in mice in vivo and this effect involves cannabinoid CB1 receptors and FAAH. In view of its low toxicity in humans, cannabidiol may represent a good candidate to normalize motility in patients with inflammatory bowel disease.
British Journal of Pharmacology (2008) 154, 1001–1008; doi:10.1038/bjp.2008.177; published online 12 May 2008